MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
-$48,259,189
(-75.36%↓ Y/Y)
Interest income
$3,715,094
(247.47%↑ Y/Y)
Loss from operations
-$51,974,283
(-81.80%↓ Y/Y)
Total costs and
expenses
$51,974,283
(81.80%↑ Y/Y)
Change in fair value
contingent consideration
$1,373,942
Research and development
$29,793,146
(73.11%↑ Y/Y)
Selling, general and
administrative
$23,555,079
(107.01%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. (IKT)